Autoimmune hemophilia at rescue

Haematologica

Volumn 94, Issue 4, 2009, Pages 459-461

  Mannucci, Pier Mannuccio ^a,b,c   Peyvandi, Flora ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b Regina Elena Foundation   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; CYCLOPHOSPHAMIDE; DESMOPRESSIN; IMMUNOSUPPRESSIVE AGENT; PREDNISONE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RITUXIMAB;

ANTIBODY TITER; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BLEEDING; CONGENITAL HEMOPHILIA; DEATH; EDITORIAL; HEMOPHILIA; HUMAN; IMMUNOLOGICAL TOLERANCE; LOADING DRUG DOSE; NONHODGKIN LYMPHOMA; RISK; THROMBOSIS; TREATMENT FAILURE; TREATMENT RESPONSE;

AUTOANTIBODIES; AUTOIMMUNITY; FACTOR VIII; HEMOPHILIA A; HEMORRHAGE;

EID: 66349115640     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.005777     Document Type: Editorial

References (14)

1. Mitchell CA, Rowell JA, Hau L, Young JP, Salem HH. A fatal thrombotic disorder associated with an acquired inhibitor of protein C. N Engl J Med 1987;317:1638-42.
2. D'Angelo A, Della Valle P, Crippa L, Pattarini E, Grimaldi LM, Vigano DS. Brief report: autoimmune protein S defi- ciency in a boy with severe thromboembolic disease. N Engl J Med 1993;328:1753-7.
3. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998;339: 1578-84.
4. Tsai HM, Lian EC. Antibodies to von Willebrand factor- cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998;339:1585-94.
5. Mannucci PM. Autoimmune haemophilia. Blood Transfus 2008;6:6-7.
6. Huth-Kuhne A, Baudo F, Collins P, Ingerslev J, Kessler CM, Levesque H, et al. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica 2009;94:566-75.
7. Franchini M, Lippi G. Acquired factor VIII inhibitors. Blood 2008;112:250-5.
8. Kavakli K, Makris M, Zulfikar B, Erhardtsen E, Abrams ZS, Kenet G. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-cen- tre, randomised, double-blind, cross-over trial. Thromb Haemost 2006;95:600-5.
9. Santagostino E, Mancuso ME, Rocino A, Mancuso G, Scaraggi F, Mannucci PM. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. J Thromb Haemost 2006;4:367-71.
10. Green D, Rademaker AW, Briet E. A prospective, ran- domized trial of prednisone and cyclophosphamide in the treatment of patients with factor VIII autoantibodies. Thromb Haemost 1993;70:753-7.
11. Collins PW, Hirsch S, Baglin TP, Dolan G, Hanley J, Makris M, et al. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. Blood 2007;109:1870-7.
12. Borg JY, Levesque H, for the SACHA study group. Epidemiology and one-year outcome in patients with acquired hemophilia in France. J Thromb Haemost 2008; 5 (Suppl 1):O.M. 062.
13. Stasi R, Brunetti M, Stipa E, Amadori S. Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood 2004;103:4424-8.
14. Mahlanghu J, Andreeva T, Macfarlane D, Reding M, Walsh C, Ritchie B, et al. Phase II open-label study eval- uating hemostasis activity, pharmacokinetics and safety of recombinant porcine factor VIII (rpFVIII, OBI-1) in hemophilia A patients with alloantibody inhibitor direct- ed against human FVIII (hFVIII). Blood 2007;110 (Suppl 1): [Abstract 783].